Skip to main content
. 2023 Dec 16;13:22406. doi: 10.1038/s41598-023-49440-3

Table 1.

Clinical demographics.

Diagnosis N Age Gender Aβ42/40 ratio pTau(181) tTau
Mean (SD) Range Females N (%) Mean (SD) Mean (SD) Mean (SD)
CU 68 64.2 (7.53) 55–85 38 (55.9) 0.112 (0.015) 29.16 (10.61) 212.4 (74.2)
MCI-AD 95 70.7 (7.33) 56–86 44 (46.3) 0.052 (0.016) *,†,$ 89.10 (46.55) *,†,#,$ 442.6 (202.5)*,†,#,$
DEM-AD 72 71.5 (9.26) 56–93 33 (45.8) 0.053 (0.015)*,†,$ 98.76 (50.91) *,†,#,$ 470.3 (255.1)*,†,#,$
MCI-other 77 68.2 (7.59) 55–84 27 (35.1) 0.131 (0.197) 28.03 (18.48) 220.0 (115.1)
DEM-other 23 70.5 (9.51) 57–89 9 (39.1) 0.112 (0.023) 30.94 (21.10) 198.8 (89.8)
NPH 57 75.0 (7.73) 57–94 20 (35.1) 0.102 (0.027) 29.00 (21.66) 204.6 (114.1)

CU = Cognitively unimpaired and includes 20 with no other specified neurological disorders, 18 patients evaluated for immune disease, 9 patients with other non-dementing neurodegenerative diseases, 6 patients with vascular disease, 5 with demyelinating disease, 4 patients with headache, 3 patients with psychiatric disease, 3 patients with idiopathic intracranial hypertension, and 1 patient with neoplasm, MCI-AD = mild cognitive impairment due to Alzheimer’s disease; DEM-AD = dementia due to Alzheimer’s disease, MCI-other = mild cognitive impairment due to other non-AD causes, DEM-other = dementia due to other non-AD causes, NPH = normal pressure hydrocephalus. Only MCI-AD and DEM-AD subjects had CSF AD biomarkers with low Aβ42/40 indicating AD. All others had normal Aβ42/40 above diagnostic threshold value. Group differences were assessed with ANOVA and p-values indicate results from post-hoc Tukey test.

* = significantly different compared to CU (p < 0.05).

† = significantly different compared to MCI-other (p < 0.05).

# = significantly different compared to DEM-other (p < 0.05).

$ = significantly different compared to NPH (p < 0.05).